secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001628280-25-007816
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q4 2024 revenue $44M (+26% YoY); net loss improves to $(108)M; 2025 rev guidance $160-180M
--------------------------------------------------------------------------------

- Q4 total revenue $44M (up 26% YoY); Cell Engineering rev $35M (+29% YoY), Biosecurity $9M.
- GAAP net loss $(108)M vs $(212)M in Q4 2023; Adj EBITDA $(57)M vs $(101)M.
- Cash flow $(55)M in Q4, improved from $(114)M in Q3; cash balance $562M.
- FY2025 guidance: total revenue $160-180M, Cell Engineering $110-130M, Biosecurity at least $50M.
- Cost-cutting achieved $190M annualized run-rate savings; targeting $250M by Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025007816/0001628280-25-007816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828025007816/dna-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-007816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer